Clinical Trials in Brazil / NCT05097365
Enrolling by invitation Not applicable

Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity

NCT05097365 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2022-01-01
Last updated
2024-05-02

Condition(s) studied

Overweight and ObesityLupus Erythematosus

Investigational drug(s) / intervention(s)

Vitamin B12 + folic acid supplementationPlacebo supplementation

Vitamin B12 + folic acid supplementation: A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.

Placebo supplementation: A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.

Study summary

Dietary supplementation with methyl donors has been demonstrated to increase DNA methylation in leucocytes whereas a limited dietary intake of methyl donors was associated with DNA hypomethylation. Considering SLE disease, previously study showed that high doses of vitamin B6 and folate were associated with less severe SLE. Furthermore, some evidences reported a relatively high incidence of decreased serum B12 levels in rheumatic patients. This led to the suggestion that diets rich in methyl group donors could have beneficial effects on SLE.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion criteria: * SLE diagnosis * Female * In pre-menopausal period * Aged between 18 to 45 years * Patients that meet the classification criteria according to Systemic Lupus International Collaborating Clinics classification criteria (SLICC) * Patients with SLEDAI score ≤ 4 on Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) * Under prednisone treatment at a dosage \<10 mg/day * Under treatment with chloroquine at a stable dose * BMI \> 18,5 kg/m2 Exclusion Criteria: * Current infection * Diabetes * Arterial hypertension * Smokers * Pregnancy * Anticoagulants use * Methotrexate use * Other autoimmune diseases * Current vitamin B12 or/and folic acid supplementation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Univsersity of Sao Paulo São Paulo Brazil

More University of Sao Paulo trials in Brazil

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05097365 on ClinicalTrials.gov ↗ ← All trials in Brazil